Myocardial Infarction - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：320頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Myocardial Infarction - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H1 2014’, provides an overview of the Myocardial Infarction’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Myocardial Infarction - Pipeline Review, H1 2014’, provides an overview of the Myocardial Infarction’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Myocardial Infarction Overview 11
Therapeutics Development 12
Pipeline Products for Myocardial Infarction - Overview 12
Pipeline Products for Myocardial Infarction - Comparative Analysis 13
Myocardial Infarction - Therapeutics under Development by Companies 14
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 20
Myocardial Infarction - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Myocardial Infarction - Products under Development by Companies 27
Myocardial Infarction - Products under Investigation by Universities/Institutes 32
Myocardial Infarction - Companies Involved in Therapeutics Development 33
Cardium Therapeutics, Inc. 33
Osiris Therapeutics, Inc. 34
AstraZeneca PLC 35
Advanced Cell Technology, Inc. 36
Athersys, Inc. 37
Merck & Co., Inc. 38
BioLineRx, Ltd. 39
FibroGen, Inc. 40
Zydus Cadila Healthcare Limited 41
A. Menarini Industrie Farmaceutiche Riunite Srl 42
Merck KGaA 43
Lixte Biotechnology Holdings, Inc. 44
Mesoblast Limited 45
Compugen Ltd. 46
Cardio3 BioSciences SA 47
RegeneRx Biopharmaceuticals, Inc. 48
NeoStem, Inc. 49
LG Life Sciences, Ltd. 50
Pluristem Therapeutics Inc. 51
Juventas Therapeutics, Inc. 52
D-Pharm Ltd. 53
Bharat Biotech International Limited 54
t2cure GmbH 55
Remedy Pharmaceuticals, Inc. 56
Fina Biotech 57
Zealand Pharma A/S 58
Angion Biomedica Corp. 59
Fate Therapeutics, Inc. 60
GliaMed, Inc. 61
Stemedica Cell Technologies, Inc. 62
TaiGen Biotechnology Co., Ltd. 63
Lacer, S.A. 64
ViroMed Co., Ltd. 65
Medestea Research & Production S.p.A. 66
Lee's Pharmaceutical Holdings Limited 67
Genextra S.p.a. 68
Vicore Pharma AB 69
Cellmid Limited 70
Stempeutics Research Private Limited 71
Serodus ASA 72
Targazyme, Inc. 73
Ampio Pharmaceuticals, Inc. 74
Aprogen, Inc. 75
Provasculon, Inc. 76
Amarantus Bioscience Holdings, Inc. 77
APT Therapeutics, Inc. 78
Stealth Peptides Inc. 79
DecImmune Therapeutics, Inc. 80
Inbiopro Solutions Pvt. Ltd. 81
Immune Pharmaceuticals, Inc. 82
Curaxys, S.L. 83
CellProthera 84
Recardio GmbH 85
BEAT BioTherapeutics Corp. 86
Capricor Therapeutics, Inc. 87
Myocardial Infarction - Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Combination Products 89
Assessment by Target 90
Assessment by Mechanism of Action 94
Assessment by Route of Administration 98
Assessment by Molecule Type 101
Drug Profiles 104
THR-100 - Drug Profile 104
amediplase - Drug Profile 106
ticagrelor - Drug Profile 107
darbepoetin alfa - Drug Profile 110
MonoCell - Drug Profile 111
anakinra - Drug Profile 113
remestemcel-L - Drug Profile 115
danegaptide - Drug Profile 117
BB-3 - Drug Profile 118
BMCs - Drug Profile 120
CEP-41750 - Drug Profile 122
MTP-131 - Drug Profile 124
BQ-123 - Drug Profile 126
RNS-60 - Drug Profile 128
AMR-001 - Drug Profile 130
Mesenchymal Bone Marrow Cells - Drug Profile 132
Autologous Myoblasts - Drug Profile 134
sodium nitrite - Drug Profile 136
REC-01 - Drug Profile 137
nitric oxide - Drug Profile 138
ZK-001 - Drug Profile 139
Stempeucel-AMI - Drug Profile 141
mecasermin - Drug Profile 142
CAP-1002 - Drug Profile 143
Alpha-1 Antitrypsin - Drug Profile 144
PF-05285401 - Drug Profile 145
burixafor - Drug Profile 148
CPI-003 - Drug Profile 150
CIGB-500 - Drug Profile 151
LC-280126 - Drug Profile 152
THR-18 - Drug Profile 153
Gene Therapy for Acute Myocardial Infarction - Drug Profile 154
FG-4539 - Drug Profile 155
GM-1485 - Drug Profile 156
CM-1 - Drug Profile 158
CGEN-855A - Drug Profile 160
CGEN-855B - Drug Profile 162
Ad5IGF-1 - Drug Profile 163
CGEN-856 - Drug Profile 164
rusalatide acetate - Drug Profile 166
LB-100 - Drug Profile 169
JVS-100 - Drug Profile 171
Drug Targeting Stromal-Derived Factor 1 - Drug Profile 173
Allo-Cure - Drug Profile 174
C3BS-GQR-1 - Drug Profile 175
Prod-4 - Drug Profile 176
CTX-101 - Drug Profile 177
glyburide - Drug Profile 178
CAMI-103 - Drug Profile 181
Hemangioblast Program - Drug Profile 183
DMI-4983 - Drug Profile 184
LA-8045 - Drug Profile 185
AMRS-001 - Drug Profile 186
C3BS-GQR-2 - Drug Profile 187
FT-101 - Drug Profile 188
C-21 - Drug Profile 190
Drug For Myocardial Infarction - Drug Profile 192
AP-102 - Drug Profile 193
PLX Cells for Acute Myocardial Infarction - Drug Profile 194
EP-1013 - Drug Profile 195
AS-605240 - Drug Profile 196
ICG-001 - Drug Profile 198
Autologous CD34 Stem Cells - Drug Profile 199
Intramyocardial Cardiospheres - Drug Profile 200
APT-102 - Drug Profile 201
ARA-290 - Drug Profile 202
JI-38 - Drug Profile 204
sildenafil citrate - Drug Profile 205
A-HSP27 - Drug Profile 206
Drugs to Inhibit Myosin for Cardiovascular Disorders - Drug Profile 207
mPTP Inhibitors - Drug Profile 208
p66Shc Protein Inhibitors - Drug Profile 209
Myocardial Infarction Program - Drug Profile 210
Adipose Tissue Derived Stem Cells - Drug Profile 211
Fc-Alpha-1 Antitrypsin - Drug Profile 212
Anti-CD20 Monoclonal Antibody - Drug Profile 213
messenger RNA Therapeutics Program - Drug Profile 214
ASC-101 - Drug Profile 215
PRV-0023 - Drug Profile 216
N2 Antibody For Myocardial Infarction - Drug Profile 217
Gene Therapy Targeting Ribonucleotide Reductase For Heart Failure And Myocardial Infarctions - Drug Profile 218
SER-130 - Drug Profile 219
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 220
Autologous Bone Marrow Derived Mesenchymal Stem Cells - Drug Profile 221
Human Pericytes + ckit Cardiac Progenitor Cells - Drug Profile 222
NL-005 - Drug Profile 223
FcAAT-2 - Drug Profile 224
C3BS-GQR-4 - Drug Profile 225
C3BS-AQR-1 - Drug Profile 226
Biglycan Therapy - Drug Profile 227
MMP Inhibitors - Drug Profile 228
Iron Oxide Nanoparticles - Drug Profile 229
VN-100 - Drug Profile 230
CGEN-856S - Drug Profile 231
Prod-3 - Drug Profile 232
ANG-4011 - Drug Profile 233
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 234
Anti-Inflammatory Therapy - Drug Profile 235
PRV-0023 - Drug Profile 236
Tumor Necrosis Factors-Alpha Antagonist - Drug Profile 237
Small Molecules for Myocardial Infarction - Drug Profile 238
RGN-352 - Drug Profile 239
VM-202 - Drug Profile 241
IBPB-005-ET - Drug Profile 243
Nerofe - Drug Profile 244
XEN-103 - Drug Profile 245
FcAAT-3 - Drug Profile 246
Stem Cell Advanced Therapies - Drug Profile 247
Myocardial Infarction - Recent Pipeline Updates 248
Myocardial Infarction - Dormant Projects 299
Myocardial Infarction - Discontinued Products 301
Myocardial Infarction - Product Development Milestones 302
Featured News & Press Releases 302
Appendix 312
Methodology 312
Coverage 312
Secondary Research 312
Primary Research 312
Expert Panel Validation 312
Contact Us 313
Disclaimer 313
List of Tables
Number of Products under Development for Myocardial Infarction, H1 2014 19
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 22
Number of Products under Development by Companies, H1 2014 (Contd..1) 23
Number of Products under Development by Companies, H1 2014 (Contd..2) 24
Number of Products under Development by Companies, H1 2014 (Contd..3) 25
Number of Products under Development by Companies, H1 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 29
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Development, H1 2014 32
Comparative Analysis by Unknown Stage Development, H1 2014 33
Products under Development by Companies, H1 2014 34
Products under Development by Companies, H1 2014 (Contd..1) 35
Products under Development by Companies, H1 2014 (Contd..2) 36
Products under Development by Companies, H1 2014 (Contd..3) 37
Products under Development by Companies, H1 2014 (Contd..4) 38
Products under Investigation by Universities/Institutes, H1 2014 39
Myocardial Infarction - Pipeline by Cardium Therapeutics, Inc., H1 2014 40
Myocardial Infarction - Pipeline by Osiris Therapeutics, Inc., H1 2014 41
Myocardial Infarction - Pipeline by AstraZeneca PLC, H1 2014 42
Myocardial Infarction - Pipeline by Advanced Cell Technology, Inc., H1 2014 43
Myocardial Infarction - Pipeline by Athersys, Inc., H1 2014 44
Myocardial Infarction - Pipeline by Merck & Co., Inc., H1 2014 45
Myocardial Infarction - Pipeline by BioLineRx, Ltd., H1 2014 46
Myocardial Infarction - Pipeline by FibroGen, Inc., H1 2014 47
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 48
Myocardial Infarction - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 49
Myocardial Infarction - Pipeline by Merck KGaA, H1 2014 50
Myocardial Infarction - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 51
Myocardial Infarction - Pipeline by Mesoblast Limited, H1 2014 52
Myocardial Infarction - Pipeline by Compugen Ltd., H1 2014 53
Myocardial Infarction - Pipeline by Cardio3 BioSciences SA, H1 2014 54
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 55
Myocardial Infarction - Pipeline by NeoStem, Inc., H1 2014 56
Myocardial Infarction - Pipeline by LG Life Sciences, Ltd., H1 2014 57
Myocardial Infarction - Pipeline by Pluristem Therapeutics Inc., H1 2014 58
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H1 2014 59
Myocardial Infarction - Pipeline by D-Pharm Ltd., H1 2014 60
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H1 2014 61
Myocardial Infarction - Pipeline by t2cure GmbH, H1 2014 62
Myocardial Infarction - Pipeline by Remedy Pharmaceuticals, Inc., H1 2014 63
Myocardial Infarction - Pipeline by Fina Biotech, H1 2014 64
Myocardial Infarction - Pipeline by Zealand Pharma A/S, H1 2014 65
Myocardial Infarction - Pipeline by Angion Biomedica Corp., H1 2014 66
Myocardial Infarction - Pipeline by Fate Therapeutics, Inc., H1 2014 67
Myocardial Infarction - Pipeline by GliaMed, Inc., H1 2014 68
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H1 2014 69
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014 70
Myocardial Infarction - Pipeline by Lacer, S.A., H1 2014 71
Myocardial Infarction - Pipeline by ViroMed Co., Ltd., H1 2014 72
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H1 2014 73
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2014 74
Myocardial Infarction - Pipeline by Genextra S.p.a., H1 2014 75
Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2014 76
Myocardial Infarction - Pipeline by Cellmid Limited, H1 2014 77
Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H1 2014 78
Myocardial Infarction - Pipeline by Serodus ASA, H1 2014 79
Myocardial Infarction - Pipeline by Targazyme, Inc., H1 2014 80
Myocardial Infarction - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 81
Myocardial Infarction - Pipeline by Aprogen, Inc., H1 2014 82
Myocardial Infarction - Pipeline by Provasculon, Inc., H1 2014 83
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2014 84
Myocardial Infarction - Pipeline by APT Therapeutics, Inc., H1 2014 85
Myocardial Infarction - Pipeline by Stealth Peptides Inc., H1 2014 86
Myocardial Infarction - Pipeline by DecImmune Therapeutics, Inc., H1 2014 87
Myocardial Infarction - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 88
Myocardial Infarction - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 89
Myocardial Infarction - Pipeline by Curaxys, S.L., H1 2014 90
Myocardial Infarction - Pipeline by CellProthera, H1 2014 91
Myocardial Infarction - Pipeline by Recardio GmbH, H1 2014 92
Myocardial Infarction - Pipeline by BEAT BioTherapeutics Corp., H1 2014 93
Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H1 2014 94
Assessment by Monotherapy Products, H1 2014 95
Assessment by Combination Products, H1 2014 96
Number of Products by Stage and Target, H1 2014 99
Number of Products by Stage and Mechanism of Action, H1 2014 103
Number of Products by Stage and Route of Administration, H1 2014 107
Number of Products by Stage and Molecule Type, H1 2014 110
Myocardial Infarction Therapeutics - Recent Pipeline Updates, H1 2014 255
Myocardial Infarction - Dormant Projects, H1 2014 306
Myocardial Infarction - Discontinued Products, H1 2014 308
List of Figures
Number of Products under Development for Myocardial Infarction, H1 2014 19
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 21
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Products, H1 2014 32
Assessment by Monotherapy Products, H1 2014 95
Number of Products by Top 10 Target, H1 2014 97
Number of Products by Stage and Top 10 Target, H1 2014 98
Number of Products by Top 10 Mechanism of Action, H1 2014 101
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 102
Number of Products by Top 10 Route of Administration, H1 2014 105
Number of Products by Stage and Top 10 Route of Administration, H1 2014 106
Number of Products by Top 10 Molecule Type, H1 2014 108
Number of Products by Stage and Top 10 Molecule Type, H1 2014 109
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 10
Global Markets Direct Report Coverage 10
Myocardial Infarction Overview 11
Therapeutics Development 12
Pipeline Products for Myocardial Infarction - Overview 12
Pipeline Products for Myocardial Infarction - Comparative Analysis 13
Myocardial Infarction - Therapeutics under Development by Companies 14
Myocardial Infarction - Therapeutics under Investigation by Universities/Institutes 20
Myocardial Infarction - Pipeline Products Glance 23
Late Stage Products 23
Clinical Stage Products 24
Early Stage Products 25
Unknown Stage Products 26
Myocardial Infarction - Products under Development by Companies 27
Myocardial Infarction - Products under Investigation by Universities/Institutes 32
Myocardial Infarction - Companies Involved in Therapeutics Development 33
Cardium Therapeutics, Inc. 33
Osiris Therapeutics, Inc. 34
AstraZeneca PLC 35
Advanced Cell Technology, Inc. 36
Athersys, Inc. 37
Merck & Co., Inc. 38
BioLineRx, Ltd. 39
FibroGen, Inc. 40
Zydus Cadila Healthcare Limited 41
A. Menarini Industrie Farmaceutiche Riunite Srl 42
Merck KGaA 43
Lixte Biotechnology Holdings, Inc. 44
Mesoblast Limited 45
Compugen Ltd. 46
Cardio3 BioSciences SA 47
RegeneRx Biopharmaceuticals, Inc. 48
NeoStem, Inc. 49
LG Life Sciences, Ltd. 50
Pluristem Therapeutics Inc. 51
Juventas Therapeutics, Inc. 52
D-Pharm Ltd. 53
Bharat Biotech International Limited 54
t2cure GmbH 55
Remedy Pharmaceuticals, Inc. 56
Fina Biotech 57
Zealand Pharma A/S 58
Angion Biomedica Corp. 59
Fate Therapeutics, Inc. 60
GliaMed, Inc. 61
Stemedica Cell Technologies, Inc. 62
TaiGen Biotechnology Co., Ltd. 63
Lacer, S.A. 64
ViroMed Co., Ltd. 65
Medestea Research & Production S.p.A. 66
Lee's Pharmaceutical Holdings Limited 67
Genextra S.p.a. 68
Vicore Pharma AB 69
Cellmid Limited 70
Stempeutics Research Private Limited 71
Serodus ASA 72
Targazyme, Inc. 73
Ampio Pharmaceuticals, Inc. 74
Aprogen, Inc. 75
Provasculon, Inc. 76
Amarantus Bioscience Holdings, Inc. 77
APT Therapeutics, Inc. 78
Stealth Peptides Inc. 79
DecImmune Therapeutics, Inc. 80
Inbiopro Solutions Pvt. Ltd. 81
Immune Pharmaceuticals, Inc. 82
Curaxys, S.L. 83
CellProthera 84
Recardio GmbH 85
BEAT BioTherapeutics Corp. 86
Capricor Therapeutics, Inc. 87
Myocardial Infarction - Therapeutics Assessment 88
Assessment by Monotherapy Products 88
Assessment by Combination Products 89
Assessment by Target 90
Assessment by Mechanism of Action 94
Assessment by Route of Administration 98
Assessment by Molecule Type 101
Drug Profiles 104
THR-100 - Drug Profile 104
amediplase - Drug Profile 106
ticagrelor - Drug Profile 107
darbepoetin alfa - Drug Profile 110
MonoCell - Drug Profile 111
anakinra - Drug Profile 113
remestemcel-L - Drug Profile 115
danegaptide - Drug Profile 117
BB-3 - Drug Profile 118
BMCs - Drug Profile 120
CEP-41750 - Drug Profile 122
MTP-131 - Drug Profile 124
BQ-123 - Drug Profile 126
RNS-60 - Drug Profile 128
AMR-001 - Drug Profile 130
Mesenchymal Bone Marrow Cells - Drug Profile 132
Autologous Myoblasts - Drug Profile 134
sodium nitrite - Drug Profile 136
REC-01 - Drug Profile 137
nitric oxide - Drug Profile 138
ZK-001 - Drug Profile 139
Stempeucel-AMI - Drug Profile 141
mecasermin - Drug Profile 142
CAP-1002 - Drug Profile 143
Alpha-1 Antitrypsin - Drug Profile 144
PF-05285401 - Drug Profile 145
burixafor - Drug Profile 148
CPI-003 - Drug Profile 150
CIGB-500 - Drug Profile 151
LC-280126 - Drug Profile 152
THR-18 - Drug Profile 153
Gene Therapy for Acute Myocardial Infarction - Drug Profile 154
FG-4539 - Drug Profile 155
GM-1485 - Drug Profile 156
CM-1 - Drug Profile 158
CGEN-855A - Drug Profile 160
CGEN-855B - Drug Profile 162
Ad5IGF-1 - Drug Profile 163
CGEN-856 - Drug Profile 164
rusalatide acetate - Drug Profile 166
LB-100 - Drug Profile 169
JVS-100 - Drug Profile 171
Drug Targeting Stromal-Derived Factor 1 - Drug Profile 173
Allo-Cure - Drug Profile 174
C3BS-GQR-1 - Drug Profile 175
Prod-4 - Drug Profile 176
CTX-101 - Drug Profile 177
glyburide - Drug Profile 178
CAMI-103 - Drug Profile 181
Hemangioblast Program - Drug Profile 183
DMI-4983 - Drug Profile 184
LA-8045 - Drug Profile 185
AMRS-001 - Drug Profile 186
C3BS-GQR-2 - Drug Profile 187
FT-101 - Drug Profile 188
C-21 - Drug Profile 190
Drug For Myocardial Infarction - Drug Profile 192
AP-102 - Drug Profile 193
PLX Cells for Acute Myocardial Infarction - Drug Profile 194
EP-1013 - Drug Profile 195
AS-605240 - Drug Profile 196
ICG-001 - Drug Profile 198
Autologous CD34 Stem Cells - Drug Profile 199
Intramyocardial Cardiospheres - Drug Profile 200
APT-102 - Drug Profile 201
ARA-290 - Drug Profile 202
JI-38 - Drug Profile 204
sildenafil citrate - Drug Profile 205
A-HSP27 - Drug Profile 206
Drugs to Inhibit Myosin for Cardiovascular Disorders - Drug Profile 207
mPTP Inhibitors - Drug Profile 208
p66Shc Protein Inhibitors - Drug Profile 209
Myocardial Infarction Program - Drug Profile 210
Adipose Tissue Derived Stem Cells - Drug Profile 211
Fc-Alpha-1 Antitrypsin - Drug Profile 212
Anti-CD20 Monoclonal Antibody - Drug Profile 213
messenger RNA Therapeutics Program - Drug Profile 214
ASC-101 - Drug Profile 215
PRV-0023 - Drug Profile 216
N2 Antibody For Myocardial Infarction - Drug Profile 217
Gene Therapy Targeting Ribonucleotide Reductase For Heart Failure And Myocardial Infarctions - Drug Profile 218
SER-130 - Drug Profile 219
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction - Drug Profile 220
Autologous Bone Marrow Derived Mesenchymal Stem Cells - Drug Profile 221
Human Pericytes + ckit Cardiac Progenitor Cells - Drug Profile 222
NL-005 - Drug Profile 223
FcAAT-2 - Drug Profile 224
C3BS-GQR-4 - Drug Profile 225
C3BS-AQR-1 - Drug Profile 226
Biglycan Therapy - Drug Profile 227
MMP Inhibitors - Drug Profile 228
Iron Oxide Nanoparticles - Drug Profile 229
VN-100 - Drug Profile 230
CGEN-856S - Drug Profile 231
Prod-3 - Drug Profile 232
ANG-4011 - Drug Profile 233
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders - Drug Profile 234
Anti-Inflammatory Therapy - Drug Profile 235
PRV-0023 - Drug Profile 236
Tumor Necrosis Factors-Alpha Antagonist - Drug Profile 237
Small Molecules for Myocardial Infarction - Drug Profile 238
RGN-352 - Drug Profile 239
VM-202 - Drug Profile 241
IBPB-005-ET - Drug Profile 243
Nerofe - Drug Profile 244
XEN-103 - Drug Profile 245
FcAAT-3 - Drug Profile 246
Stem Cell Advanced Therapies - Drug Profile 247
Myocardial Infarction - Recent Pipeline Updates 248
Myocardial Infarction - Dormant Projects 299
Myocardial Infarction - Discontinued Products 301
Myocardial Infarction - Product Development Milestones 302
Featured News & Press Releases 302
Appendix 312
Methodology 312
Coverage 312
Secondary Research 312
Primary Research 312
Expert Panel Validation 312
Contact Us 313
Disclaimer 313
List of Tables
Number of Products under Development for Myocardial Infarction, H1 2014 19
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 22
Number of Products under Development by Companies, H1 2014 (Contd..1) 23
Number of Products under Development by Companies, H1 2014 (Contd..2) 24
Number of Products under Development by Companies, H1 2014 (Contd..3) 25
Number of Products under Development by Companies, H1 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H1 2014 28
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 29
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Development, H1 2014 32
Comparative Analysis by Unknown Stage Development, H1 2014 33
Products under Development by Companies, H1 2014 34
Products under Development by Companies, H1 2014 (Contd..1) 35
Products under Development by Companies, H1 2014 (Contd..2) 36
Products under Development by Companies, H1 2014 (Contd..3) 37
Products under Development by Companies, H1 2014 (Contd..4) 38
Products under Investigation by Universities/Institutes, H1 2014 39
Myocardial Infarction - Pipeline by Cardium Therapeutics, Inc., H1 2014 40
Myocardial Infarction - Pipeline by Osiris Therapeutics, Inc., H1 2014 41
Myocardial Infarction - Pipeline by AstraZeneca PLC, H1 2014 42
Myocardial Infarction - Pipeline by Advanced Cell Technology, Inc., H1 2014 43
Myocardial Infarction - Pipeline by Athersys, Inc., H1 2014 44
Myocardial Infarction - Pipeline by Merck & Co., Inc., H1 2014 45
Myocardial Infarction - Pipeline by BioLineRx, Ltd., H1 2014 46
Myocardial Infarction - Pipeline by FibroGen, Inc., H1 2014 47
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H1 2014 48
Myocardial Infarction - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2014 49
Myocardial Infarction - Pipeline by Merck KGaA, H1 2014 50
Myocardial Infarction - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 51
Myocardial Infarction - Pipeline by Mesoblast Limited, H1 2014 52
Myocardial Infarction - Pipeline by Compugen Ltd., H1 2014 53
Myocardial Infarction - Pipeline by Cardio3 BioSciences SA, H1 2014 54
Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals, Inc., H1 2014 55
Myocardial Infarction - Pipeline by NeoStem, Inc., H1 2014 56
Myocardial Infarction - Pipeline by LG Life Sciences, Ltd., H1 2014 57
Myocardial Infarction - Pipeline by Pluristem Therapeutics Inc., H1 2014 58
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H1 2014 59
Myocardial Infarction - Pipeline by D-Pharm Ltd., H1 2014 60
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H1 2014 61
Myocardial Infarction - Pipeline by t2cure GmbH, H1 2014 62
Myocardial Infarction - Pipeline by Remedy Pharmaceuticals, Inc., H1 2014 63
Myocardial Infarction - Pipeline by Fina Biotech, H1 2014 64
Myocardial Infarction - Pipeline by Zealand Pharma A/S, H1 2014 65
Myocardial Infarction - Pipeline by Angion Biomedica Corp., H1 2014 66
Myocardial Infarction - Pipeline by Fate Therapeutics, Inc., H1 2014 67
Myocardial Infarction - Pipeline by GliaMed, Inc., H1 2014 68
Myocardial Infarction - Pipeline by Stemedica Cell Technologies, Inc., H1 2014 69
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H1 2014 70
Myocardial Infarction - Pipeline by Lacer, S.A., H1 2014 71
Myocardial Infarction - Pipeline by ViroMed Co., Ltd., H1 2014 72
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H1 2014 73
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2014 74
Myocardial Infarction - Pipeline by Genextra S.p.a., H1 2014 75
Myocardial Infarction - Pipeline by Vicore Pharma AB, H1 2014 76
Myocardial Infarction - Pipeline by Cellmid Limited, H1 2014 77
Myocardial Infarction - Pipeline by Stempeutics Research Private Limited, H1 2014 78
Myocardial Infarction - Pipeline by Serodus ASA, H1 2014 79
Myocardial Infarction - Pipeline by Targazyme, Inc., H1 2014 80
Myocardial Infarction - Pipeline by Ampio Pharmaceuticals, Inc., H1 2014 81
Myocardial Infarction - Pipeline by Aprogen, Inc., H1 2014 82
Myocardial Infarction - Pipeline by Provasculon, Inc., H1 2014 83
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2014 84
Myocardial Infarction - Pipeline by APT Therapeutics, Inc., H1 2014 85
Myocardial Infarction - Pipeline by Stealth Peptides Inc., H1 2014 86
Myocardial Infarction - Pipeline by DecImmune Therapeutics, Inc., H1 2014 87
Myocardial Infarction - Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2014 88
Myocardial Infarction - Pipeline by Immune Pharmaceuticals, Inc., H1 2014 89
Myocardial Infarction - Pipeline by Curaxys, S.L., H1 2014 90
Myocardial Infarction - Pipeline by CellProthera, H1 2014 91
Myocardial Infarction - Pipeline by Recardio GmbH, H1 2014 92
Myocardial Infarction - Pipeline by BEAT BioTherapeutics Corp., H1 2014 93
Myocardial Infarction - Pipeline by Capricor Therapeutics, Inc., H1 2014 94
Assessment by Monotherapy Products, H1 2014 95
Assessment by Combination Products, H1 2014 96
Number of Products by Stage and Target, H1 2014 99
Number of Products by Stage and Mechanism of Action, H1 2014 103
Number of Products by Stage and Route of Administration, H1 2014 107
Number of Products by Stage and Molecule Type, H1 2014 110
Myocardial Infarction Therapeutics - Recent Pipeline Updates, H1 2014 255
Myocardial Infarction - Dormant Projects, H1 2014 306
Myocardial Infarction - Discontinued Products, H1 2014 308
List of Figures
Number of Products under Development for Myocardial Infarction, H1 2014 19
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H1 2014 20
Number of Products under Development by Companies, H1 2014 21
Number of Products under Investigation by Universities/Institutes, H1 2014 27
Comparative Analysis by Late Stage Development, H1 2014 30
Comparative Analysis by Clinical Stage Development, H1 2014 31
Comparative Analysis by Early Stage Products, H1 2014 32
Assessment by Monotherapy Products, H1 2014 95
Number of Products by Top 10 Target, H1 2014 97
Number of Products by Stage and Top 10 Target, H1 2014 98
Number of Products by Top 10 Mechanism of Action, H1 2014 101
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 102
Number of Products by Top 10 Route of Administration, H1 2014 105
Number of Products by Stage and Top 10 Route of Administration, H1 2014 106
Number of Products by Top 10 Molecule Type, H1 2014 108
Number of Products by Stage and Top 10 Molecule Type, H1 2014 109
